CD274 and metastatic melanoma: Given the increasing number of possible treatment options for metastatic melanoma patients in first-line therapy (aPD1+aCTLA4, or aPD1, or BRAFi+MEKi, or aPD1/aPDL1+BRAFi+MEKi), we believe that the use of a biomarker, such as PD-L1 expression level, could be very useful.